CLINICAL SIGNIFICANT P-GLYCOPROTEIN DRUG INTERACTIONS?

被引：0
|
作者：
Lee, Caroline A. [1 ]
Fenner, Katherine S. [2 ]
Kempshall, Sarah [2 ]
Cook, Jack [3 ]
Ware, Joseph Alan [4 ]
Troutman, Matthew D. [5 ]
机构：
[1] Pfizer Inc, La Jolla Labs, Dept PDM, San Diego, CA 92121 USA
[2] Pfizer Global Res & Dev, Pharmacokinet Dynam & Metab, Sandwich, Kent, England
[3] Pfizer, Clin Pharmacol, New London, CT 06320 USA
[4] Pfizer Global Rsch & Develop, Dept PKDM, Ann Arbor, MI 48105 USA
[5] Pfizer Inc, Dept PDM, Groton, CT 06340 USA
来源：
DRUG METABOLISM REVIEWS | 2008年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
316
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [31] Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin
    Ling, Spencer Y.
    Huizinga, Robert B.
    Mayo, Patrick R.
    Larouche, Richard
    Freitag, Derrick G.
    Aspeslet, Launa J.
    Foster, Robert T.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (06) : 1039 - 1050
  • [32] P-GLYCOPROTEIN TRANSPORTER IN DRUG DEVELOPMENT
    Prachayasittikul, Veda
    Prachayasittikul, Virapong
    EXCLI JOURNAL, 2016, 15 : 113 - 118
  • [33] Role of P-glycoprotein in drug disposition
    Tanigawara, Y
    THERAPEUTIC DRUG MONITORING, 2000, 22 (01) : 137 - 140
  • [34] P-GLYCOPROTEIN AND DRUG-RESISTANCE
    CHOU, TH
    CORBETT, TH
    YOST, C
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1984, 25 (MAR): : 331 - 331
  • [35] The contribution of P-glycoprotein to clinical pharmacokinetic interactions between lenalidomide and temsirolimus
    Yang, Xiaoxia
    Craig, Hofmeister C.
    Rozewski, Darlene M.
    Lee, Seungsoo
    Chen, Ping
    Johnson, Amy J.
    Liu, Zhongfa
    Hade, Erinn M.
    Ji, Jia
    Schaaf, Larry J.
    Benson, Don M.
    Kraut, Eric H.
    Hicks, William J.
    Chan, Kenneth K.
    Chen, Ching-Shih
    Farag, Sherif S.
    Grever, Michael R.
    Byrd, John C.
    Phelps, Mitch A.
    CANCER RESEARCH, 2011, 71
  • [36] Clinical drug resistance: The role of factors other than P-glycoprotein
    Kaye, SB
    AMERICAN JOURNAL OF MEDICINE, 1995, 99 : S40 - S44
  • [37] Study of drug interactions with efflux pumps using P-glycoprotein containing membranes
    Xia, CQ
    Liu, N
    Gan, LS
    Miwa, G
    DRUG METABOLISM REVIEWS, 2003, 35 : 151 - 151
  • [38] The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter
    Romsicki, Y
    Sharom, FJ
    BIOCHEMISTRY, 1999, 38 (21) : 6887 - 6896
  • [39] Toxic digoxin-drug interactions: The major role of renal p-glycoprotein
    Koren, G
    Woodland, C
    Ito, S
    VETERINARY AND HUMAN TOXICOLOGY, 1998, 40 (01) : 45 - 46
  • [40] P-glycoprotein system as a determinant of drug interactions: The case of digoxin-verapamil
    Verschraagen, M
    Koks, CHW
    Schellens, JHM
    Beijnen, JH
    PHARMACOLOGICAL RESEARCH, 1999, 40 (04) : 301 - 306
12345